I'd like to explore your thoughts on why you give a 50 percent chance of success to the concluding AD trial. To get to that point, you have to give equal weight to pros and cons.
Here is a list of pros:
1. PDD cognitive results, strongly positive on a scale with a 70 percent correlation to the AD primary endpoint.
2. Successful PDD and Rett trials, in light of an MOA theory with consistent scientific support that implies a cross-CNS effect. The MOA is supported by evidence of SIR engagement in trials and biomarkers that occur across trialed CNS diseases. It is also supported by across-the-board clinical improvements in PDD and Rett.
3. Anecdote-level responders within the 2A AD trial, with the current trial designed to bring out this potential (mild AD, 50 mg doses)
4. Excellent safety profile
What is your list of cons that is of equal weight?
Market Data 
Markets 
AI
